PL396568A1 - Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny - Google Patents

Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny

Info

Publication number
PL396568A1
PL396568A1 PL396568A PL39656802A PL396568A1 PL 396568 A1 PL396568 A1 PL 396568A1 PL 396568 A PL396568 A PL 396568A PL 39656802 A PL39656802 A PL 39656802A PL 396568 A1 PL396568 A1 PL 396568A1
Authority
PL
Poland
Prior art keywords
desmethyl
crystalline
dosage form
venlafaxine succinate
preparation
Prior art date
Application number
PL396568A
Other languages
English (en)
Other versions
PL212943B1 (pl
Inventor
Anthony Francis Hadfield
Syed Muazfar Shah
Michael William Winkley
Karen Wiggins Sutherland
James Andrew Provost
Aeri Park
Rex Alvyn Shipplett
Brenton William Russel
Beat Theodor Weber
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL396568(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth filed Critical Wyeth
Publication of PL396568A1 publication Critical patent/PL396568A1/pl
Publication of PL212943B1 publication Critical patent/PL212943B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL396568A 2001-02-12 2002-02-11 Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postac dawkowania, doustna postac dawkowania oraz zastosowanie PL212943B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26821401P 2001-02-12 2001-02-12
US29796301P 2001-06-13 2001-06-13

Publications (2)

Publication Number Publication Date
PL396568A1 true PL396568A1 (pl) 2012-02-13
PL212943B1 PL212943B1 (pl) 2012-12-31

Family

ID=26952945

Family Applications (2)

Application Number Title Priority Date Filing Date
PL364605A PL211788B1 (pl) 2001-02-12 2002-02-11 Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna zawierająca ten związek, farmaceutyczna postać dawkowania, doustna postać dawkowania oraz zastosowanie krystalicznego bursztynianu O-demetylo-wenlafaksyny do wytwarzania leku
PL396568A PL212943B1 (pl) 2001-02-12 2002-02-11 Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postac dawkowania, doustna postac dawkowania oraz zastosowanie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL364605A PL211788B1 (pl) 2001-02-12 2002-02-11 Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna zawierająca ten związek, farmaceutyczna postać dawkowania, doustna postać dawkowania oraz zastosowanie krystalicznego bursztynianu O-demetylo-wenlafaksyny do wytwarzania leku

Country Status (30)

Country Link
US (5) US6673838B2 (pl)
EP (3) EP1360169B2 (pl)
JP (1) JP4220243B2 (pl)
KR (1) KR100875610B1 (pl)
CN (2) CN101671260A (pl)
AR (2) AR032671A1 (pl)
AT (1) ATE369330T1 (pl)
AU (1) AU2002250058B2 (pl)
BR (1) BR0207157A (pl)
CA (2) CA2436668C (pl)
CY (1) CY1106952T1 (pl)
DE (1) DE60221642T3 (pl)
DK (1) DK1360169T3 (pl)
EA (1) EA011451B1 (pl)
ES (1) ES2290281T5 (pl)
HN (1) HN2002000030A (pl)
HU (1) HUP0303128A3 (pl)
IL (4) IL157340A0 (pl)
MX (1) MXPA03007043A (pl)
NO (1) NO328807B1 (pl)
NZ (1) NZ539791A (pl)
PA (1) PA8539901A1 (pl)
PE (1) PE20020877A1 (pl)
PL (2) PL211788B1 (pl)
PT (1) PT1360169E (pl)
SI (1) SI1360169T1 (pl)
TW (1) TWI318201B (pl)
UY (1) UY27175A1 (pl)
WO (1) WO2002064543A2 (pl)
ZA (1) ZA200307116B (pl)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914826A (pt) 1998-10-30 2001-11-06 Ajinomoto Kk Processo de cristalização de cristais de éster metìlico de n- [n-(3,3-dimetilbutil)-l-alfa-aspartil] -l-fenilalanina
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
AU2002250058B2 (en) * 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
US20050244498A1 (en) * 2001-09-14 2005-11-03 Biovail Laboratories, Inc. Modified-release compositions of at least one form of venlafaxine
UA80543C2 (en) 2001-12-04 2007-10-10 Wyeth Corp Method for the preparation of o-desmethylvenlafaxine
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
AU2003247515A1 (en) * 2002-06-10 2003-12-22 Wyeth Novel formate salt of o-desmethyl-venlafaxine
BR0313836A (pt) * 2002-08-29 2005-06-21 Arachnova Therapeutics Ltd Novos usos terapêuticos de 4-(2-fluorofenil)-6-metil-2-(1-piperazinil)tieno[2,3-d]pi rimidina
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
JP2004359665A (ja) * 2003-05-30 2004-12-24 Rohm & Haas Co 生体利用性増強剤を含有する治療組成物
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
AU2005212166A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate O-desmethylvenlafaxine salts and uses thereof
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7439280B2 (en) * 2004-04-06 2008-10-21 Basf Corporation Lignocellulosic composite material and method for preparing the same
US20060020015A1 (en) * 2004-07-22 2006-01-26 Wyeth Method for treating nervous system disorders and conditions
CA2574315A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
AU2005266997A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
US20060193911A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co., Controlled release venlafaxine formulations
DE602006010343D1 (de) * 2005-03-31 2009-12-24 Wyeth Corp Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
CN1955159B (zh) * 2005-06-17 2010-11-24 山东绿叶制药有限公司 用于阻断5-羟色胺以及去甲基肾上腺素再摄取的化合物,其制备方法及其用途
WO2007005961A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US20070015828A1 (en) * 2005-07-15 2007-01-18 Wyeth Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
US7687520B2 (en) 2005-07-15 2010-03-30 Wyeth Llc Serotonin and norepinephrine reuptake inhibitors and uses thereof
US7595340B2 (en) 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
JP2009502798A (ja) * 2005-07-21 2009-01-29 ワイス 神経系障害および状態の処置方法
GT200600397A (es) * 2005-09-07 2007-08-28 Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales
GT200600396A (es) * 2005-09-07 2007-04-23 Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales
CN1332946C (zh) * 2005-10-21 2007-08-22 中国人民解放军军事医学科学院放射与辐射医学研究所 作用于中枢神经系统的前药
PT1954669E (pt) * 2005-12-01 2015-10-23 Auspex Pharmaceuticals Inc Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
CA2629609A1 (en) * 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
WO2007071404A1 (en) 2005-12-20 2007-06-28 Synthon B.V. Process for making desvenlafaxine
WO2007120923A1 (en) 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Substantially pure o-desmethylvenlafaxine and processes for preparing it
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
SI2020996T1 (sl) * 2006-05-16 2012-03-30 Gilead Sciences Inc Postopek in sestavki za zdravljenje hematološkihmalignosti
US20090137846A1 (en) * 2006-07-26 2009-05-28 Valerie Niddam-Hildesheim Processes for the synthesis of O-Desmethylvenlafaxine
CA2656166A1 (en) * 2006-07-26 2008-01-31 Teva Pharmaceutical Industries Ltd. Processes for the synthesis of o-desmethylvenlafaxine
US20080221356A1 (en) * 2006-07-26 2008-09-11 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20090069601A1 (en) * 2006-07-26 2009-03-12 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20090062572A1 (en) 2006-07-26 2009-03-05 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20100121108A1 (en) * 2006-08-04 2010-05-13 Medichem, S.A. Process for synthesizing desvenlafaxine free base and salts or solvates thereof
CA2659295A1 (en) * 2006-08-08 2008-02-14 Generics [Uk] Limited Novel hydrate form of o-desmethyl venlafaxine succinate
EP2074082A1 (en) * 2006-10-18 2009-07-01 Generics (UK) Limited Polymorphs of o-desmethyl venlafaxine succinate
AR063376A1 (es) * 2006-10-25 2009-01-28 Wyeth Corp Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento
KR20090092338A (ko) * 2006-12-21 2009-08-31 화이자 프로덕츠 인크. 2-((4-(1-메틸-4-(피리딘-4-일)-1ｈ-피라졸-3-일)페녹시)메틸)퀴놀린의 숙시네이트 염
AR064507A1 (es) * 2006-12-22 2009-04-08 Medichem Sa Nuevas formas solidas cristalinas de forma base de o-desvenlafaxina
US7820716B2 (en) * 2007-01-08 2010-10-26 Mai De Ltd Crystalline polymorphs of desvenlafaxine succinate and their preparations
WO2008090465A2 (en) * 2007-01-22 2008-07-31 Medichem, S.A. Process for synthesizing desvenlafaxine free base and salts or salvates thereof
US20100076086A1 (en) * 2007-01-31 2010-03-25 Merck Development Centre Private Limited Plot 1 A/2 Process for the preparation of o-desmethyl venlafaxine
NZ599480A (en) * 2007-02-21 2013-10-25 Sunovion Pharmaceuticals Inc Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof
WO2008110338A1 (en) * 2007-03-09 2008-09-18 Synthon B.V. Polymorph of desvenlafaxine succinate
IN2009DN05509A (pl) * 2007-03-14 2010-04-30 Teva Pharma
SI2125698T1 (sl) 2007-03-15 2016-12-30 Auspex Pharmaceuticals, Inc. Devterirani d9-venlafaksin
WO2008156748A2 (en) * 2007-06-15 2008-12-24 Teva Pharmaceutical Industries Ltd. Crystal forms of o-desmethylvenlafaxine succinate
TR200909798T1 (tr) * 2007-07-12 2010-05-21 Dr. Reddy's Laboratories Ltd. O-desmetilvenlafaksin.
WO2009010990A2 (en) * 2007-07-16 2009-01-22 Matrix Laboratories Limited Process for the preparation of o-desmethylvenlafaxine succinate polymorphic forms
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
US20090076162A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched desvenlafaxine
CA2702664A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US20110046231A1 (en) * 2007-10-22 2011-02-24 Actavis Group Ptc Ehf Solid forms of (±)-o-desmethylvenlafaxine salts
NZ585368A (en) * 2007-10-26 2012-07-27 Generics Uk Ltd Process for preparing o-desmethylvenlafaxine
CA2706775A1 (en) * 2007-11-26 2009-06-04 Teva Pharmaceutical Industries Ltd. Crystal forms of o-desmethylvenlafaxine fumarate
EP2085377A1 (en) 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Novel salts of O-desmethyl-venlafaxine
EP2262758A4 (en) * 2008-03-12 2011-12-07 Reddys Lab Ltd Dr O-desmethylvenlafaxine SALTS
WO2009118758A2 (en) * 2008-03-24 2009-10-01 Sun Pharmaceutical Industries Ltd. Novel crystalline forms of desvenlafaxine succinate
IN2008CH00818A (pl) * 2008-04-01 2009-10-09 Actavis Group Ptc Ehf
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
EP2119695A1 (en) 2008-05-16 2009-11-18 Krka Preparation of O-desmethylvenlafaxine salts
EP2119696A1 (en) * 2008-05-16 2009-11-18 Krka Preparation of O-desmethylvenlafaxine salts
EP2297087A2 (en) * 2008-06-16 2011-03-23 Teva Pharmaceutical Industries Ltd. Solid states of o-desmethylvenlaf axine salts
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
US20100016638A1 (en) * 2008-07-21 2010-01-21 Zdenko Hamersak Method for preparation of o-desmethylvenlafaxine using polythiolates
JP2011529481A (ja) * 2008-07-30 2011-12-08 ジェネリクス・（ユーケー）・リミテッド Ｏ−デスメチルベンラファキシンの調製方法
KR101041960B1 (ko) * 2008-08-14 2011-06-16 주식회사 루미맥스테크놀러지 파워 ｌｅｄ를 구비하는 램프 장치
EP2191822A1 (en) 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
CZ2008756A3 (cs) * 2008-11-27 2010-03-24 Zentiva, A. S. Zpusob prípravy desvenlafaxinu a jeho solí
ES2343050B1 (es) * 2008-12-16 2011-06-14 Chemo Iberica, S.A. Procedimiento para la preparacion de desvenlafaxina y sus sales de adicion de acido farmaceuticamente aceptables.
CZ301820B6 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
CZ302145B6 (cs) 2009-07-15 2010-11-10 Zentiva, K. S. Zpusob prípravy desvenlafaxinu a jeho solí
WO2011007136A2 (en) 2009-07-16 2011-01-20 Cipla Limited Process for the preparation of o-desmethyl venlafaxine and intermediate for use therein
US20110098506A1 (en) * 2009-10-26 2011-04-28 Intas Pharmaceuticals Limited Method of preparing o-desmethylvenlafaxine
WO2011072703A1 (en) 2009-12-16 2011-06-23 Pharmathen S.A. Process for the preparation of o-desmethyl-venlafaxine and salts thereof
US20110184067A1 (en) * 2010-01-25 2011-07-28 Intas Pharmaceuticals Ltd. O-desmethylvenlafaxine succinate polymorph & process for preparing thereof
EP2539313A2 (en) 2010-03-29 2013-01-02 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
MX2012010659A (es) * 2010-03-31 2013-03-05 Wockhardt Ltd Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales.
CZ303249B6 (cs) 2010-04-06 2012-06-20 Zentiva, K.S. Zpusob výroby 4-(2-(substituovaných)-1-(1-hydroxycyklohexyl)ethyl)fenolu O-demethylací jejich methyletheru pomocí nepáchnoucích aromatických thiolu
CN102212014B (zh) * 2010-04-09 2013-12-25 江苏豪森医药集团有限公司 O-去甲基-文拉法辛的谷氨酸盐的晶型、其制备方法及其在医药上的应用
US20130034604A1 (en) 2010-05-14 2013-02-07 Alembic Pharmaceuticals Limited Extended release formulations of desvenlafaxine base
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
KR101477154B1 (ko) 2010-10-01 2014-12-29 산동 루예 파마슈티칼 컴파니 리미티드 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도
US8933123B2 (en) 2010-10-08 2015-01-13 Cadila Healthcare Limited Polymorphic forms of O-desmethyl-venlafaxine succinate
KR20140045925A (ko) 2011-03-17 2014-04-17 루핀 리미티드 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
KR20140030156A (ko) 2011-04-12 2014-03-11 루핀 리미티드 방출-조절되는 데스벤라팍신 약학 조성물
US8481596B2 (en) 2011-06-08 2013-07-09 Lupin Limited Polymomorph of desvenlafaxine benzoate
UY35091A (es) * 2012-10-24 2014-05-30 Onyx Therapeutics Inc Formulaciones de liberacion modificada para oprozomib
CN104666291A (zh) * 2013-11-26 2015-06-03 山东绿叶制药有限公司 去甲基文拉法辛苯甲酸酯类化合物在制备改善性功能障碍药物中的应用
CN104352469A (zh) * 2014-11-20 2015-02-18 哈尔滨圣吉药业股份有限公司 一种琥珀酸去甲文拉法辛缓释片及其制备方法
CN106146323B (zh) * 2015-04-03 2021-05-25 石药集团中奇制药技术（石家庄）有限公司 一种琥珀酸去甲文拉法辛一水合物新晶型及制备方法
MX367362B (es) 2016-06-29 2019-08-16 Alparis Sa De Cv Nuevas formas solidas de desvenlafaxina.
WO2018146529A1 (en) * 2017-02-09 2018-08-16 R L Finechem Private Limited A process for preparation of1-[2-(dimethylamino)-1-(4-hydroxyphenyl) ethyl]-cyclohexanol and salts thereof
CN107082745A (zh) * 2017-04-21 2017-08-22 上海华源医药科技发展有限公司 一种改进的ⅰ型去甲文拉法辛琥珀酸盐的生产方法
WO2019014338A1 (en) * 2017-07-11 2019-01-17 Universal Stabilization Technologies, Inc. METHOD FOR PRESERVING BIOPHARMACEUTICAL PRODUCTS
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
TWI805601B (zh) 2017-08-11 2023-06-21 南韓商愛茉莉太平洋股份有限公司 醫藥組成物及抑制其形成結晶的方法
KR102518632B1 (ko) 2018-04-18 2023-04-06 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
TR201820634A2 (tr) 2018-12-27 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Desvenlafaksi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8902209D0 (en) 1989-02-01 1989-03-22 Wyeth John And Brother Limited Preparation of cyclohexanol derivatives and novel thioamide intermediates
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2139000A1 (en) 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
CA2138998A1 (en) 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE69429895T2 (de) * 1993-06-28 2002-08-29 American Home Products Corp., Madison Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
EP1245228A3 (en) † 1994-02-14 2002-10-09 Wyeth Medicament for the inducement of cognition enhancement
US5594586A (en) * 1994-05-02 1997-01-14 The United States Of America As Represented By The Secretary Of The Air Force Photorefractive limiting quadratic processor
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5506270A (en) † 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
AU3075197A (en) † 1996-05-21 1997-12-09 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Novel methods of o-demethylation and n-deprotection
EP1952802A3 (en) † 1997-10-01 2009-06-17 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
NZ516083A (en) † 1999-05-27 2003-08-29 Acusphere Inc Porous drug matrices and methods of manufacture thereof
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
US20020022662A1 (en) 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
AU2002250058B2 (en) * 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
UA80543C2 (en) * 2001-12-04 2007-10-10 Wyeth Corp Method for the preparation of o-desmethylvenlafaxine
AU2003247515A1 (en) 2002-06-10 2003-12-22 Wyeth Novel formate salt of o-desmethyl-venlafaxine
TWI306092B (en) 2003-03-11 2009-02-11 Wyeth Corp Process for preparation of phenethylamine derivatives
AU2005212166A1 (en) 2004-02-06 2005-08-25 Wyeth Multiparticulate O-desmethylvenlafaxine salts and uses thereof

Also Published As

Publication number Publication date
KR100875610B1 (ko) 2008-12-26
ATE369330T1 (de) 2007-08-15
HK1057885A1 (en) 2004-04-23
US20030045583A1 (en) 2003-03-06
EA200300873A1 (ru) 2003-12-25
US6673838B2 (en) 2004-01-06
HUP0303128A2 (hu) 2003-12-29
WO2002064543A3 (en) 2002-12-12
DE60221642T2 (de) 2008-05-21
AR082076A2 (es) 2012-11-07
CN100567253C (zh) 2009-12-09
PT1360169E (pt) 2007-10-29
CA2666611A1 (en) 2002-08-22
AR032671A1 (es) 2003-11-19
MXPA03007043A (es) 2003-11-18
EP1864967A1 (en) 2007-12-12
US7291347B2 (en) 2007-11-06
US20050096479A1 (en) 2005-05-05
IL209444A0 (en) 2011-07-31
US20090018208A1 (en) 2009-01-15
PE20020877A1 (es) 2002-11-12
EP1360169B2 (en) 2017-05-24
IL157340A0 (en) 2004-02-19
PL211788B1 (pl) 2012-06-29
EP1360169A2 (en) 2003-11-12
PL212943B1 (pl) 2012-12-31
HN2002000030A (es) 2004-06-07
TWI318201B (en) 2009-12-11
ES2290281T5 (es) 2017-09-11
US7026508B2 (en) 2006-04-11
ES2290281T3 (es) 2008-02-16
EA011451B1 (ru) 2009-04-28
DE60221642D1 (en) 2007-09-20
EP1360169B1 (en) 2007-08-08
NO20033538D0 (no) 2003-08-11
NZ539791A (en) 2006-11-30
IL200255A (en) 2010-12-30
AU2002250058B2 (en) 2007-08-16
JP4220243B2 (ja) 2009-02-04
CA2436668A1 (en) 2002-08-22
DE60221642T3 (de) 2017-10-26
HUP0303128A3 (en) 2008-03-28
US20070037884A1 (en) 2007-02-15
CN101671260A (zh) 2010-03-17
CY1106952T1 (el) 2012-09-26
NO328807B1 (no) 2010-05-18
PA8539901A1 (es) 2005-05-10
US20040044241A1 (en) 2004-03-04
PL364605A1 (pl) 2004-12-13
UY27175A1 (es) 2002-09-30
CA2436668C (en) 2009-05-26
DK1360169T3 (da) 2007-11-26
IL209444A (en) 2012-10-31
JP2004529877A (ja) 2004-09-30
IL157340A (en) 2010-04-15
NO20033538L (no) 2003-08-11
CN1501909A (zh) 2004-06-02
WO2002064543A2 (en) 2002-08-22
EP2319826A1 (en) 2011-05-11
ZA200307116B (en) 2005-02-23
BR0207157A (pt) 2004-02-17
SI1360169T1 (sl) 2007-12-31
KR20030077614A (ko) 2003-10-01

Similar Documents

Publication Publication Date Title
PL396568A1 (pl) Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny
HUP0204226A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
HUP0301315A3 (en) Benzothiazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
HUP0302519A3 (en) Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
HUP0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
PL356358A1 (en) Solid dosage form of someticone for oral administration
HUP0301069A3 (en) Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use
HUP0401619A3 (en) Phenethanolamine derivatives, process for their preparation and pharmaceutical composition containing them
HUP0402161A3 (en) Nicotin-or isonicotin benzothiazole derivatives, process for their preparation and pharmaceutical compositions containing them
SI1417206T1 (sl) Novi H piridazin onski derivati farmacevtski sestavki ki jih vsebujejo in postopek za pripravo aktivne sestavine
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
PL370554A1 (pl) Nowe związki i ich zastosowanie w medycynie, sposób ich wytwarzania oraz kompozycje farmaceutyczne zawierajace te związki
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
HUP0202233A3 (en) Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them
HU0100489D0 (en) New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them
HUP0401350A3 (en) Novel imidazopyridine compounds with therapeutic effect, process for their preparation and pharmaceutical compositions containing them
AU2002348829A1 (en) Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
HUP0204001A3 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0303105A3 (en) Novel aminocyclohexane derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0303361A3 (en) Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0401082A3 (en) Substituted 4-aminocyclohexanols, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
RECP Rectifications of patent specification